Axsome Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M | $0 |
| Cost of Revenue | — | — | — | $5.2M |
| Gross Profit | — | — | — | $-5.2M |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $183.3M | $187.1M | $97.9M | $57.9M |
| SG&A Expense | $570.6M | $411.4M | $323.1M | $159.3M |
| Operating Income | $-166.8M | $-280.6M | $-231.8M | $-179.8M |
| Operating Margin | -26.1% | -72.7% | -85.7% | — |
| Interest Expense | $-15.9M | $-21.6M | $-20.0M | $-9.7M |
| Pretax Income | $-183.7M | $-287.1M | $-238.3M | $-187.1M |
| Income Tax Expense | $-530.0K | $85.0K | $960.0K | $0 |
| Net Income | $-183.2M | $-287.2M | $-239.2M | $-187.1M |
| Net Margin | -28.7% | -74.5% | -88.4% | — |
| EPS (Basic) | $-3.68 | $-5.99 | $-5.27 | $-4.60 |
| EPS (Diluted) | $-3.68 | $-5.99 | $-5.27 | $-4.60 |
| Shares Outstanding (Basic) | 49.7M | 47.9M | 45.4M | 40.7M |
| Shares Outstanding (Diluted) | 49.7M | 47.9M | 45.4M | 40.7M |
| Dividends Per Share | — | — | — | — |